Lovestone Simon, Francis Paul, Kloszewska Iwona, Mecocci Patrizia, Simmons Andrew, Soininen Hilkka, Spenger Christian, Tsolaki Magda, Vellas Bruno, Wahlund Lars-Olof, Ward Malcolm
NIHR Specialist Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and King's College London, Institute of Psychiatry, London SE5 8AF, United Kingdom.
Ann N Y Acad Sci. 2009 Oct;1180:36-46. doi: 10.1111/j.1749-6632.2009.05064.x.
There is an urgent need for Alzheimer's disease (AD) biomarkers-especially in the context of clinical trials. Biomarkers for early diagnosis, disease progression, and prediction are most critical, and disease-modification therapy development may depend on the discovery and validation of such markers. AddNeuroMed is a cross European, public/private consortium developed for AD biomarker discovery. We report here the development and design of AddNeuroMed and the progress toward the development of plasma markers. Despite the obstacles to such markers, we have identified a range of markers including CFH and A2M, both of which have been independently replicated. The experience of AddNeuroMed leads us to three overall conclusions. First, collaboration is essential. Second, design is paramount and combining modalities, such as imaging and proteomics, may be informative. Third, animal models are valuable in biomarker research. Most importantly, we have learned that plasma markers are feasible.
迫切需要阿尔茨海默病（AD）生物标志物——尤其是在临床试验的背景下。用于早期诊断、疾病进展和预测的生物标志物最为关键，而疾病修饰疗法的开发可能依赖于此类标志物的发现和验证。AddNeuroMed是一个为发现AD生物标志物而组建的跨欧洲公共/私人财团。我们在此报告AddNeuroMed的开发与设计以及血浆标志物开发的进展。尽管此类标志物存在诸多障碍，但我们已经鉴定出一系列标志物，包括CFH和A2M，二者均已得到独立验证。AddNeuroMed的经验让我们得出三个总体结论。第一，合作至关重要。第二，设计至关重要，将成像和蛋白质组学等多种模式结合起来可能会提供有用信息。第三，动物模型在生物标志物研究中很有价值。最重要的是，我们认识到血浆标志物是可行的。
